Form 4: LENZ CFO buys 7,500 shares at $8.57

LENZ Therapeutics CFO Daniel R. Chevallard purchased 7,500 common shares on March 27, 2026 at $8.57, increasing his direct holdings to 12,886.

Summary

• On March 27, 2026, Chief Financial Officer Daniel R. Chevallard purchased 7,500 shares of LENZ Therapeutics common stock at $8.57 per share in an open-market transaction (code "P").
• Following the purchase, Chevallard directly owns 12,886 shares.
• Ownership is reported as direct (D).
• The transaction was signed/certified by the reporting person on March 30, 2026.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a mildly positive signal due to open-market buying by the CFO, though the modest size limits impact on the broader investment thesis.

Positives

• Insider purchase by the CFO indicates alignment with shareholders.
• Purchase price was $8.57 per share; approximate total outlay ~$64,275.
• Direct ownership increased to 12,886 shares.

Negatives

• No operational or financial performance information is provided in this Form 4.
• Transaction size is modest, limiting its standalone signaling power.

Future Outlook

No forward-looking guidance or outlook included.

Industry Context

StockSavvy.ai notes that insider purchases in small- and mid-cap biotech are generally viewed as positive confidence signals, though single transactions of this modest size rarely move valuation absent clinical, regulatory, or commercial catalysts.

Comparison to Industry Standards

• Transaction size (~$64k) is consistent with typical small- to mid-cap biotech insider buys, which often fall below $100k.
• As with peers, an insider purchase of this magnitude is usually a supportive sentiment data point rather than a standalone catalyst.
• Larger insider accumulation events (often >$250k) tend to carry stronger signaling effects than transactions of this scale.

Stakeholder Impact

• CFO increased direct equity stake to 12,886 shares, modestly enhancing management-shareholder alignment.
• No dilution or capital structure impact; shares were acquired on the open market.

Key Dates

Recommendation

The insider purchase by the CFO is a constructive sentiment indicator but is modest in size and does not provide new information on operations, financials, or catalysts. Maintaining a hold view is appropriate pending material clinical, regulatory, or financial updates.

Keywords

LENZ Therapeutics, LENZ, insider buying, Form 4, Daniel R. Chevallard, CFO, common stock, open market purchase, SEC